This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

M. J. Friedrich

JAMA. 2002;287:2640-2643.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Francisco—Targeting precancerous lesions with chemopreventive agents that delay, halt, or even reverse disease progression can greatly reduce the cancer burden, say many researchers. Malignant tumors, like cardiovascular disease, generally take years to emerge. This lengthy period of development provides an opportunity to interrupt a precancer's march toward malignancy. The hope is that interventions against precancerous lesions will reduce cancer deaths, just as treatments during the early stages of the cardiovascular disease process have prevented deaths from heart disease.

Recognition of the close association between premalignant lesions and invasive cancer has prompted the American Association for Cancer Research (AACR) to organize a task force that recommends focusing efforts to treat and prevent established precancers called intraepithelial neoplasia (IEN). The full task force report appeared in the February issue of Clinical Cancer Research (2002;8:314-346).

Because few chemopreventive agents have been approved for clinical use, one of the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?